GeneDx, the genetic‑testing company spun out of the National Institutes of Health, highlighted strong operational metrics at the Wells Fargo healthcare conference. Second‑quarter test volume grew 32% compared with the same period last year, and the firm expects full‑year volume to expand around 30% with a similar pace anticipated for the second half of 2024 and into 2025.
The company returned to profitability one quarter ahead of internal forecasts, driven by a gross margin near 70% (69% over the trailing twelve months). Genome‑sequencing cost of goods sold remains roughly double that of exome sequencing. Current collection rates sit at about 32% for genome cases and 35% for exome cases; management targets eventual rates near 70%. Feeley noted that each five‑percentage‑point improvement in collection rates at existing volumes could add roughly $50 million of revenue.
GeneDx holds approximately $200 million of pro‑forma cash and recently secured a $50 million debt facility from Blackstone Life Sciences. A $25 million cost‑reduction program has been fully implemented. The company’s market capitalization stands at $2.54 billion, with a beta of 2.01 and a current ratio of 3.3. Analyst consensus rates the stock a strong buy with price targets ranging from $74 to $103.
Operationally, the firm has processed nearly 3 million genetic tests since its inception 26 years ago and maintains the GeneDx Infinity dataset, which contains over 1 million exome and genome sequences and eight million phenotypic data points. Genome tests accounted for 32% of Q2 volume, down from 40% in Q1 after the launch of the Exome‑to‑Genome Reflex product in mid‑February 2024.
GeneDx’s market penetration remains deep among specialist clinicians. Eight out of ten U.S. expert geneticists order from the company, with roughly 30% patient penetration. About one‑third of pediatric neurologists and one‑third of level‑3 and level‑4 NICUs are active customers, though testing penetration in NICUs is still in the mid‑single‑digit range. The firm added roughly 50 sales representatives to target general pediatrics, aiming at 25,000 of the 60,000 U.S. pediatricians who have previously ordered genetic tests.
Payer dynamics show 88% of commercial insurers now cover genome sequencing, yet claims were submitted to covered payers only 68% of the time in Q2. Prior authorization remains required by 99% of payers, and more than two‑thirds of denials are procedural rather than medical‑necessity disputes. Integration with Epic Aura is underway, with an 18‑month timeline.
CEO Kevin Feeley emphasized the unmet need in rare‑disease diagnostics, noting that one in ten Americans lives with an undiagnosed rare condition. He described the rare‑disease diagnostic market as roughly two decades behind oncology and signaled that GeneDx is positioned to accelerate diagnosis, drug discovery and therapeutic development.
The company’s growth outlook hinges on expanding test volumes, improving collection rates and deepening payer relationships, while leveraging its extensive genomic dataset to support research and clinical decision‑making.
